Key result
The SARS-CoV-2 C.1.2 lineage showed reduced neutralization sensitivity to plasma from vaccinees and D614G-infected individuals, similar to the Beta and Delta variants.
Observational (n=166)
Global genomic surveillance of SARS-CoV-2 has identified variants associated with increased transmissibility, neutralization resistance and disease severity. Here we report the emergence of the PANGO lineage C.1.2, detected at low prevalence in South Africa and eleven other countries. The emergence of C.1.2, associated with a high substitution rate, includes changes within the spike protein that have been associated with increased transmissibility or reduced neutralization sensitivity in SARS-CoV-2 VOC/VOIs. Like Beta and Delta, C.1.2 shows significantly reduced neutralization sensitivity to plasma from vaccinees and individuals infected with the ancestral D614G virus. In contrast, convalescent donors infected with either Beta or Delta showed high plasma neutralization against C.1.2. These functional data suggest that vaccine efficacy against C.1.2 will be equivalent to Beta and Delta, and that prior infection with either Beta or Delta will likely offer protection against C.1.2.
No takes yet. Share an insight, caveat, or question.
Scheepers et al. (2021) conducted an observational in SARS-CoV-2 (n=166). SARS-CoV-2 C.1.2 lineage vs. D614G, Beta, and Delta variants was evaluated on Neutralization sensitivity. The SARS-CoV-2 C.1.2 lineage showed reduced neutralization sensitivity to plasma from vaccinees and D614G-infected individuals, similar to the Beta and Delta variants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: